211 related articles for article (PubMed ID: 35978032)
1. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma.
Xie X; Zheng M; Guo W; Zhou Y; Xiang Z; Li Y; Yang J
Sci Rep; 2022 Aug; 12(1):13969. PubMed ID: 35978032
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
3. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
4. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
5. MAFLD: an optimal framework for understanding liver cancer phenotypes.
Crane H; Gofton C; Sharma A; George J
J Gastroenterol; 2023 Oct; 58(10):947-964. PubMed ID: 37470858
[TBL] [Abstract][Full Text] [Related]
6. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Li L; Dai J; Natarajan Y; Yu X; Asch SM; El-Serag HB
Hepatology; 2020 Mar; 71(3):808-819. PubMed ID: 31675427
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
Vitale A; Svegliati-Baroni G; Ortolani A; Cucco M; Dalla Riva GV; Giannini EG; Piscaglia F; Rapaccini G; Di Marco M; Caturelli E; Zoli M; Sacco R; Cabibbo G; Marra F; Mega A; Morisco F; Gasbarrini A; Foschi FG; Missale G; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Oliveri F; Pelizzaro F; Ramirez Morales R; Cillo U; Trevisani F; Miele L; Marchesini G; Farinati F;
Gut; 2023 Jan; 72(1):141-152. PubMed ID: 34933916
[TBL] [Abstract][Full Text] [Related]
8. Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma.
Xiong KG; Lin TS; Kong JF; Lin QB; Chen LF; Ke KY
Medicine (Baltimore); 2023 Mar; 102(9):e33062. PubMed ID: 36862923
[TBL] [Abstract][Full Text] [Related]
9. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
10. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
[TBL] [Abstract][Full Text] [Related]
12. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.
Lee YB; Ha Y; Chon YE; Kim MN; Lee JH; Park H; Kim KI; Kim SH; Rim KS; Hwang SG
Clin Mol Hepatol; 2019 Mar; 25(1):52-64. PubMed ID: 30360031
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
14. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.
Xiong KG; Ke KY; Chen LF; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):366-372. PubMed ID: 35466065
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
16. Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.
Sun YD; Zhang H; Li YM; Han JJ
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189086. PubMed ID: 38342420
[TBL] [Abstract][Full Text] [Related]
17. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
[TBL] [Abstract][Full Text] [Related]
18. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.
Chan AW; Wong GL; Chan HY; Tong JH; Yu YH; Choi PC; Chan HL; To KF; Wong VW
J Gastroenterol Hepatol; 2017 Mar; 32(3):667-676. PubMed ID: 27547913
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
[TBL] [Abstract][Full Text] [Related]
20. NAFLD and MAFLD as emerging causes of HCC: A populational study.
Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
